Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Gut health may hold key to preventing mania relapse

NCT ID NCT03383874

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether taking a daily probiotic supplement could prevent relapse in people recently hospitalized for mania. Over 24 weeks, 66 participants received either the probiotic or a placebo. The main goal was to see if the probiotic reduced the need for re-hospitalization. Researchers also tracked mood symptoms, thinking skills, and gut bacteria changes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Probiotic supplement containing Lactobacillus rhamnosus and Bifidobacterium animalis subsp. lactis
What this could lead to
If it works, this could offer a simple, safe add-on treatment to help people with bipolar disorder stay stable after a manic episode.
What could go wrong
This is a small, early-stage trial with only 66 participants, so results may not apply to everyone. The effect may be small or not better than placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

67 people

The number who actually took part.

Started

Sep 2018

Finished

Sep 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Capacity for written informed consent * Currently (or within the last 3 weeks) admitted to inpatient hospital for symptoms of mania. * Primary Axis I diagnosis (DSM-5) at time of admission of bipolar I (single manic episode, most recent episode manic, or most recent episode mixed) OR schizoaffective disorder, bipolar type (manic or mixed state). * Proficient in the English language. * Available to attend follow-up visits. Exclusion Criteria: * Substance- or medically-induced symptoms of mania at time of assessment. * HIV infection or other immunodeficiency condition (such as receiving cancer chemotherapy). * A serious medical condition that affects brain or cognitive functioning (e.g., epilepsy, serious head injury, concussion involving loss of consciousness, brain tumor, or other neurological disorder). Note that Hepatitis-C is not an exclusion criterion unless the participant has an acute infection. * Poorly controlled comorbid medical condition. * Major surgery in the last year. * History of weight loss surgery. * Diagnosis of Intellectual Disability or history of severe learning disorder. * Diagnosis of alcohol or substance use disorder (moderate/severe) according to DSM-5 criteria within the last 3 months, or has a positive drug toxicity screen proximate to the time of recruitment. * History of IV drug use. * Participated in any investigational drug trial in the past 30 days. * Abnormal electrolyte levels. * AST and ALT \> 3 times upper limit of normal. * Pregnant, breastfeeding, or planning to become pregnant during the study period. * Documented celiac disease (as such persons should be on a gluten-free diet as this is the standard care). Of note, we are not limiting the study to individuals with elevated levels of gliadin or casein antibodies as we intend to look at these levels as a predictor of response.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bipolar I disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Psychoneuroendocrine Research Program

    Dallas, Texas, 75235, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.